GlassScriptPhysician profile
James C Omay
NPI 1902836604
$2,101.61
in general payments reported to CMS, 2019-2025
29 companies · $550 in 2025
The $550 reported for 2025 was more than what 82% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $610 · 2023: $246 · 2024: $458 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $950.91 | 2021-2025 | Real Intelligence, Bone Anchors With Arthroscopic Delivery System, Legion |
| Novo Nordisk INC | $156.51 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $131.83 | 2022-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Exact Sciences Corporation | $80.27 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $78.97 | 2024-2025 | Voquezna |
| Edwards Lifesciences Corporation | $72.99 | 2022-2024 | Sapien 3 Ultra Resilia |
| Pacira Pharmaceuticals Incorporated | $58.50 | 2022-2025 | Zilretta, Iovera, Exparel |
| Alk-Abello, INC | $53.72 | 2023 | Grastek, Ragwitek, Odactra |
| Kowa Pharmaceuticals America, INC. | $52.58 | 2022-2023 | Seglentis |
| Vertex Pharmaceuticals Incorporated | $52.30 | 2025 | |
| Amgen INC. | $51.36 | 2023-2024 | Repatha, Otezla, Prolia |
| Solventum Corporation | $34.17 | 2025 | Prevena |
| Ultragenyx Pharmaceutical INC. | $33.28 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $30.69 | 2022 | |
| Glaxosmithkline, LLC. | $29.59 | 2023-2024 | Trelegy Ellipta, Arexvy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $22.59 | 2024 | Gemtesa |
| Anika Therapeutics, INC. | $22.19 | 2021 | |
| Integra Lifesciences Corporation | $20.19 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Abbvie INC. | $19.64 | 2023 | |
| Abbott Laboratories | $18.18 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $17.88 | 2024 | |
| Dexcom, INC. | $15.54 | 2022 | |
| Heraeus Medical, LLC. | $14.78 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.61 | 2025 | Nuzyra |
| Avanos Medical | $14.37 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.33 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $13.97 | 2022 | |
| Lundbeck LLC | $13.62 | 2024 | Rexulti |
| Pacira Therapeutics, INC. | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Omay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.